Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It’s a great idea to select tomorrow's potential winners and hold on as their stories unfold. If you're ...
This biotech company has a track record of commercializing products and delivering growth. It also has strengths in research and development. When you think of biotech companies, you may think of ...
EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. The San Francisco-headquartered company is ...
Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Pittsburgh's biotech sector ...
EyePoint (EYPT), Janux (JANX), Kyverna (KYTX), and Viking (VKTX) have analyst targets implying 179% to 384% upside. Janux and Kyverna hold the highest upside projections at 384% and 308% respectively, ...
Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...
‘My scientific career is essentially over.’ A brain drain imperils Massachusetts’ biomedical future.
A prominent cancer scientist is uprooting his Harvard University lab of two decades and moving it to Texas. A laid-off expert on aging abandoned academia for a more secure municipal research job in ...
Registration Questions? **Please note we have pricing tiers based on ticket availability. Ticket prices will increase once we sell out of the current pricing tier. We cannot redeem a lower price once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results